Toll-like receptors as modulators of mesenchymal stem cells

• Published in: Frontiers in immunology Vol. 3; p. 182
• Main Authors: Delarosa, Olga, Dalemans, Wilfried, Lombardo, Eleuterio
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Research Foundation 01.01.2012
• Subjects: Immunology; cell therapy; mesenchymal stem cells; toll-like receptor
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2012.00182

Mesenchymal stem cells (MSCs) have differentiation and immunomodulatory properties that make them interesting tools for the treatment of degenerative disorders, allograft rejection, or inflammatory and autoimmune diseases. Biological properties of MSCs can be modulated by the inflammatory microenvironment they face at the sites of injury or inflammation. Indeed, MSCs do not constitutively exert their immunomodulating properties but have to be primed by inflammatory mediators released from immune cells and inflamed tissue. A polarization process, mediated by Toll-like receptors (TLRs), toward either an anti-inflammatory or a pro-inflammatory phenotype has been described for MSCs. TLRs have been linked to allograft rejection and the perpetuation of chronic inflammatory diseases (e.g., Crohn's disease, rheumatoid arthritis) through the recognition of conserved pathogen-derived components or endogenous ligands (danger signals) produced upon injury. Interest in understanding the effects of TLR activation on MSCs has greatly increased in the last few years since MSCs will likely encounter TLR ligands at sites of injury, and it has been proven that the activation of TLRs in MSCs can modulate their function and therapeutic effect.